Gupta R C, Dickson E R, McDuffie F C, Baggenstoss A H
Am J Med. 1982 Aug;73(2):192-8. doi: 10.1016/0002-9343(82)90178-4.
A longitudinal study, examining the levels of immune complexes serially for three years, in serum from 88 patients with primary biliary cirrhosis was performed by the Raji cell radioimmunoassay. Studies of the association of autoimmune features in primary biliary cirrhosis and the effect of D-penicillamine therapy in relation to the levels of complexes were carried out. Twenty-two patients (25 percent) were found to have autoimmune features, such as Sjögren's syndrome, rheumatoid-like arthritis, scleroderma, Raynaud's disease, and Hashimoto's thyroiditis. In this subset of patients with primary biliary cirrhosis, a significantly higher prevalence (86 percent) of circulating immune complexes was detected compared with those patients showing no autoimmune features (60 percent). In addition, patients with associated autoimmune features had higher mean levels of immune complexes (259.7 micrograms AHG eq/ml) compared with those without autoimmune features (202.1 micrograms AHG eq/ml). The mean levels of complement C4, reflecting activation of classic complement pathway, were significantly lower in patients with elevated immune complexes and associated autoimmune features. The mean level of immune complexes in 13 patients receiving D-penicillamine, in contrast to the placebo group, decreased at one year but subsequently was greater than the initial level. Patients who had normal levels of immune complexes and received penicillamine therapy continued to have complex levels within the normal range for up to three years of follow-up study, but patients receiving placebo showed significantly elevated levels at subsequent intervals. Thus, levels of immune complexes in primary biliary cirrhosis may reflect the association with autoimmune features.
通过Raji细胞放射免疫分析法,对88例原发性胆汁性肝硬化患者的血清进行了一项为期三年的纵向研究,连续检测免疫复合物水平。开展了原发性胆汁性肝硬化自身免疫特征的相关性研究以及青霉胺治疗对复合物水平影响的研究。发现22例患者(25%)具有自身免疫特征,如干燥综合征、类风湿样关节炎、硬皮病、雷诺病和桥本甲状腺炎。在这一原发性胆汁性肝硬化患者亚组中,与无自身免疫特征的患者(60%)相比,循环免疫复合物的患病率显著更高(86%)。此外,具有相关自身免疫特征的患者免疫复合物平均水平(259.7微克抗人球蛋白当量/毫升)高于无自身免疫特征的患者(202.1微克抗人球蛋白当量/毫升)。反映经典补体途径激活的补体C4平均水平,在免疫复合物升高且伴有自身免疫特征的患者中显著更低。与安慰剂组相比,13例接受青霉胺治疗的患者免疫复合物平均水平在1年时下降,但随后高于初始水平。免疫复合物水平正常且接受青霉胺治疗的患者在长达三年的随访研究中复合物水平持续处于正常范围内,但接受安慰剂治疗的患者在随后各时间段显示水平显著升高。因此,原发性胆汁性肝硬化中免疫复合物水平可能反映与自身免疫特征的相关性。